U.S. Markets open in 4 hrs 31 mins
  • S&P Futures

    3,776.75
    -12.75 (-0.34%)
     
  • Dow Futures

    30,671.00
    -110.00 (-0.36%)
     
  • Nasdaq Futures

    11,489.25
    -40.25 (-0.35%)
     
  • Russell 2000 Futures

    1,700.00
    -8.00 (-0.47%)
     
  • Crude Oil

    107.29
    +1.53 (+1.45%)
     
  • Gold

    1,793.40
    -13.90 (-0.77%)
     
  • Silver

    19.74
    -0.61 (-3.01%)
     
  • EUR/USD

    1.0460
    -0.0023 (-0.2197%)
     
  • 10-Yr Bond

    2.9720
    0.0000 (0.00%)
     
  • Vix

    28.89
    +0.73 (+2.59%)
     
  • GBP/USD

    1.2103
    -0.0072 (-0.5954%)
     
  • USD/JPY

    135.5250
    -0.2030 (-0.1496%)
     
  • BTC-USD

    19,593.49
    +321.27 (+1.67%)
     
  • CMC Crypto 200

    421.69
    -9.77 (-2.27%)
     
  • FTSE 100

    7,177.47
    +8.19 (+0.11%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

UPDATE 2-U.S. FDA approves Marinus Pharma's drug to treat seizures; shares jump

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Adds analyst comment, shares)

March 18 (Reuters) - The U.S. health regulator has approved Marinus Pharmaceuticals Inc's lead drug to treat seizures associated with a rare genetic disorder in patients two years of age and older, the company said on Friday, sending its shares soaring around 36%.

The oral drug, which will be sold under the brand name Ztalmy, is for treatment of seizures associated with CDKL5 deficiency disorder, a rare genetic epilepsy.

Ztalmy is expected to be commercially available in the United States in July following scheduling by the U.S. Drug Enforcement Administration, Marinus said in a statement.

Marinus has priced the drug at about $133,000 per patient per year at the wholesale level, while after discounts, including for Medicaid patients, it will cost an average of $105,000 per patient per year, Chief Executive Officer Scott Braunstein told Reuters.

At the wholesale level, the chronic medication translates to $2,425 per bottle, Braunstein said.

Cowen and Co analyst Joseph Thome expects the drug to garner peak sales of $71 million in the U.S. in 2029 for the treatment of CDKL5 deficiency disorder.

Ztalmy exhibits anti-seizure and anti-anxiety activity by affecting a type of protein in the central nervous system called GABAA receptor.

The approval by the Food and Drug Administration was based on data from a late-stage study in 101 patients that showed a 30.7% median reduction in 28-day major motor seizure frequency in patients treated with the drug, as compared to a 6.9% decline in those receiving placebo. (Reporting by Leroy Leo and Mrinalika Roy in Bengaluru; Editing by Maju Samuel and Shailesh Kuber)